Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)

• Status: Completed
• Trial end date: 2023-01-10

Summary

Comparative, Randomized, Single Dose, Two-way Crossover Bioequivalence Study to determine the bioequivalence of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Versus Vigil 200 mg Tablets (Teva GmbH, Germany)

• Phase: Phase 1

Details

• Lead Sponsor: Genuine Research Center, Egypt
• Collaborator: Chemipharm Pharmaceutical Industries, Egypt
• Treatments: Modafinil